Aromatase Inhibitor

Identifier: CI-DRUG-00000079
Entity page: /drug/aromatase-inhibitor ↗
Edges: 48

Neighbours: 9 cancers2 variants10 trials
Drawn: 21 of 21 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Aromatase Inhibitor predicts response to …PREDICTS_RESPONSE_TO2 of 2
← predicts response to	KMT2C Lossdeletion_cna	resistance	B	Malignant Breast Neoplasm	1	Curated	civic	graph →
← predicts response to	ESR1 S463PSNV	resistance	D

Aromatase Inhibitor investigated for …INVESTIGATED_FOR1 of 1
→ investigated for	Malignant Breast Neoplasmcancer_family	supports	B	Malignant Breast Neoplasm	1	Curated	civic	graph →

Aromatase Inhibitor investigated for …INVESTIGATED_FOR1 of 1

→ investigated for

Malignant Breast Neoplasmcancer_family

supports

Malignant Breast Neoplasm

Curated

Aromatase Inhibitor investigated in trials for …INVESTIGATED_IN_TRIALSderived9 of 9
→ investigated in trials for	Malignant Breast Neoplasmcancer_family 24 trials (9 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Breast Neoplasm	24	Observed	clinicaltrials	graph →
→ investigated in trials for	Breast Neoplasm 7 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Breast Neoplasm	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Breast Ductal Carcinoma In Situ 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Breast Ductal Carcinoma In Situ	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Early Stage Breast Carcinoma 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Early Stage Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	HER2-Low Breast Carcinoma 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	HER2-Low Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	HER2-Positive Breast Carcinoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	HER2-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Hormone Receptor-Positive Breast Carcinoma 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Hormone Receptor-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Endometrial Neoplasm 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Endometrial Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Solid Neoplasm 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Solid Neoplasm	1	Observed	clinicaltrials	graph →

Aromatase Inhibitor studied in …STUDIED_INderived10 of 36show all (up to 200)
→ studied in	NCT07222267Phase 1 · recruiting An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors · 36 trials list this drug (13 active)	—	—	Solid Neoplasm,Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05384119Phase 1 · terminated Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer · 36 trials list this drug (13 active)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT06440967Phase 3 · active not recruiting A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy · 36 trials list this drug (13 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT07796880Phase 2 · recruiting Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive， Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer · 36 trials list this drug (13 active)	—	—	Breast Neoplasm,Early Stage Breast Carcinoma,HER2-Low Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07782840Phase 2 · not yet recruiting QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemotherapy · 36 trials list this drug (13 active)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT03959891Phase 1 · active not recruiting AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC) · 36 trials list this drug (13 active)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT06218303Phase 1 · recruiting Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ · 36 trials list this drug (13 active)	—	—	Breast Ductal Carcinoma In Situ	1	Observed	clinicaltrials	graph →
→ studied in	NCT05043506completed European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies · 36 trials list this drug (13 active)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04188548Phase 1 · active not recruiting A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer · 36 trials list this drug (13 active)	—	—	Malignant Breast Neoplasm,Malignant Endometrial Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT07618923Phase 2 · not yet recruiting Neoadjuvant Dalpiciclib + AI → SHR-A1811 for HR+/HER2-Low Breast Cancer · 36 trials list this drug (13 active)	—	—	Breast Neoplasm,Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths